Medikamentöse Therapien in der Raucherentwöhnung

Raucherentwöhnung - Nikotinanhängigkeit - Suchtprävention

smoking cessation - tobacco dependence - addiction prevention

Literatur

• 1 Batra A. Bupropion – wirkungsvolle oder nebenwirkungsreiche Raucherentwöhnungstherapie.  Sucht. 2001;  47 294-298
• 2 Batra A, Bühringer G, Watzl H. Sponsoring und Werbung der pharmazeutischen Industrie: Nutzen, Bedenken, Nachteile.  Sucht. 2007;  53 198-200
• 3 Batra A, Schütz C G, Lindinger P. Tabakabhängigkeit.  In: Schmidt LG, Gastpar M, Falkai P, Gaebel W, Evidenzbasierte Suchtmedizin. Behandlungsleitlinie Substanzbezogene Störungen. Köln; Deutscher Ärzte-Verlag 2006: 91-142
• 4 Cahill K, Stead L F, Lancaster T. Nicotine receptor partial agonist for smoking cessation (review).  Cochrane Library. 2007 ;  (Issue 1) , CD006103)
• 5 Etter J F. Cytisine for smoking cessation.  Arch Intern Med. 2006;  166 1553-1559
• 6 Etter J F, Burri M, Stapleton J. The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis.  Addiction. 2007;  102 815-822
• 7 Fagerström K, Hughes J. Varenicline in the treatment of tobacco dependence.  Neuropsychiatric Dis Treatm. 2008;  4 (2) 353-363
• 8 Fiore M C, Jaén C R, Baker T B. et al . Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services.  Public Health Services. 2008; 
• 9 Hoch E, Muehlig S, Höfler M. et al . How prevalent is smoking and nicotine dependence in primary care in Germany?.  Addiction. 2004;  99 1586-1598
• 10 Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation.  Cochrane Database Syst Rev. 2004 ;  (Issue 4) , CD00031)
• 11 Hurt R D, Sachs D P, Glover E D. et al . A comparison of sustained-release bupropion and placebo for smoking cessation.  N Engl J Med. 1997;  337 1195-202
• 12 Jorenby D E, Leischow S J, Nides M A. et al . A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.  N Engl J Med. 1999;  340 685-691
• 13 Raw M, Anderson P, Batra A. et al . Recommendations panel: WHO Europe evidence based recommendations on the treatment of tobacco dependence.  Tobacco Control. 2002;  11 44-46
• 14 Rollema H, Chambers L K, Coe J W, Glowa J, Hurst R S, Lebel L A, Lu Y, Mansbach R S, Mather R J, Rovetti C C, Sands S B, Schaeffer E, Schulz D W, Tingley 3rd  F D, Williams K E. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.  Neuropharmacology. 2007;  52 985-994
• 15 Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR.  Addiction. 2004;  99 1462-1469
• 16 Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Update Software. Oxford; Cochrane Database Syst Rev 2006 Issue 2)
• 17 Slemmer J E, Martin B R, Damaj M I. Bupropion is a nicotinic antagonist.  J Pharmacol Exp Ther. 2000;  295 321-327
• 18 Stapleton J A, Russell M A, Feyerabend C. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice.  Addiction. 1995;  90 31-42
• 19 Stapleton J A, Watson L, Spirling L I, Smith R, Milbrandt A, Ratcliffe M, Sutherland G. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.  Addiction. 2008;  103 146-154
• 20 Swanson N A, Burroughs C C, Long M A. et al . Controlled trial for smoking cessation in a Navy shipboard population using nicotine patch, sustained-release bupropion, or both.  Mil Med. 2003;  168 830-834